Skip to main content
. 2021 May 13;12(14):4196–4208. doi: 10.7150/jca.58522

Figure 5.

Figure 5

miR-1246 regulated drug-sensitivity of leukemia cells by targeting AXIN2 and GSK-3β and further influencing P-gp activity. A, The mRNA expression level of AXIN2 and GSK-3β in K562/ADM and HL-60/RS cells was analyzed comparing to their chemo-sensitive parental cells (a, b, c, d). B, The protein immunoblotting was used to test the expression of AXIN2 and GSK-3β in K562, K562/ADM and HL-60, HL-60/RS cells. C, Comparing to NC inhibitor transfected chemo-resistant leukemia cells, mRNA (a and b) and protein (c) level of AXIN2 and GSK-3β in miR-1246 inhibitor transfected chemo-resistant leukemia cells were analysed (* P < 0.05, comparing to their negative control, respectively). D AXIN2 and GSK-3β were detected using RT-qPCR and western blot in miR-1246 mimics and NC mimics transfected chemo-sensitive leukemia cells. E, Position 313-320 of AXIN2 3'UTR and position 510-516 of GSK-3β 3'UTR were identified as potential targets of miR-1246. F, Dual luciferase reporter assay was performed to verify the interaction between miR-1246 and AXIN2 or miR-1246 and GSK-3β. pRL-TK renilla luciferase plasmid was co-transfected for normalization (* P < 0.05, comparing to their negative control, respectively). E, Protein immunoblotting assay was used to check the differences of multidrug resistant protein (P-gp) and key factors in Wnt/β-catenin pathway and its downstream factors with or without miR-1246 inhibitor transfection.